Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

406 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y. Ito K, et al. Among authors: tateyama m. Support Care Cancer. 2022 Jun;30(6):5351-5359. doi: 10.1007/s00520-022-06936-4. Epub 2022 Mar 15. Support Care Cancer. 2022. PMID: 35292848 Free PMC article.
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y. Nakano S, et al. Among authors: tateyama m. BMJ Open. 2022 May 9;12(5):e048833. doi: 10.1136/bmjopen-2021-048833. BMJ Open. 2022. PMID: 35534074 Free PMC article.
Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer.
Komatsu Y, Yuki S, Sogabe S, Fukushima H, Nakatsumi H, Kobayashi Y, Iwanaga I, Nakamura M, Hatanaka K, Miyagishima T, Kudo M, Munakata M, Meguro T, Tateyama M, Sakata Y. Komatsu Y, et al. Among authors: tateyama m. Acta Oncol. 2012 Sep;51(7):867-72. doi: 10.3109/0284186X.2012.682629. Epub 2012 May 4. Acta Oncol. 2012. PMID: 22554343 Free article. Clinical Trial.
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
Nakatsumi H, Komatsu Y, Yuki S, Sogabe S, Tateyama M, Muto S, Kudo M, Kato K, Miyagishima T, Uebayashi M, Meguro T, Oba K, Asaka M. Nakatsumi H, et al. Among authors: tateyama m. Chemotherapy. 2012;58(6):439-44. doi: 10.1159/000345920. Epub 2013 Jan 29. Chemotherapy. 2012. PMID: 23364217 Free article. Clinical Trial.
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP.
Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N. Kobayashi Y, et al. Among authors: tateyama m. Future Oncol. 2015;11(4):617-27. doi: 10.2217/fon.14.251. Future Oncol. 2015. PMID: 25686117 Free article. Clinical Trial.
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y. Komatsu Y, et al. Among authors: tateyama m. Cancer Sci. 2015 Jul;106(7):891-5. doi: 10.1111/cas.12675. Epub 2015 May 27. Cancer Sci. 2015. PMID: 25872578 Free PMC article. Clinical Trial.
Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Komatsu Y, Yuuki S, Fuse N, Takei M, Kato T, Miyagishima T, Kudo M, Kunieda Y, Tateyama M, Wakahama O, Meguro T, Ohizumi H, Watanabe M, Akita H, Sakata Y, Asaka M. Komatsu Y, et al. Among authors: tateyama m. Jpn J Clin Oncol. 2005 Feb;35(2):88-9. doi: 10.1093/jjco/hyi025. Jpn J Clin Oncol. 2005. PMID: 15709093 Clinical Trial.
406 results